MyFinsight
Home
Blog
About
Cash and cash
equivalents
$12,841K
(-26.35%↓ Y/Y)
Other current assets
$11,260K
(1031.66%↑ Y/Y)
Prepaid expenses
$3,074K
(-40.31%↓ Y/Y)
Restricted cash
$960K
(-15.79%↓ Y/Y)
Inventory
$483K
(-4.55%↓ Y/Y)
Accounts receivable, net
$82K
(382.35%↑ Y/Y)
Total current assets
$28,700K
(13.69%↑ Y/Y)
Property and equipment,
net
$99K
(-69.44%↓ Y/Y)
Total assets
$28,799K
(11.67%↑ Y/Y)
Accumulated deficit
-$747,498K
(-10.47%↓ Y/Y)
Total liabilities and
stockholders' (deficit)...
$28,799K
(11.67%↑ Y/Y)
Total stockholders'
(deficit) equity
-$115,460K
(-7.24%↓ Y/Y)
Additional
paid-in-capital
$632,007K
(11.09%↑ Y/Y)
Common stock, 0.001 par
value, 200,000 shares...
$31K
(-48.33%↓ Y/Y)
Total liabilities
$144,259K
(8.09%↑ Y/Y)
Total current
liabilities
$137,149K
(310.92%↑ Y/Y)
Derivative liabilities
$7,110K
(172.31%↑ Y/Y)
Current portion of
long-term debt
$104,451K
(1031.27%↑ Y/Y)
Accounts payable
$18,783K
(12.53%↑ Y/Y)
Other current
liabilities-Nonrelated Party
$9,837K
(3742.58%↑ Y/Y)
Accrued expenses
$3,921K
(-22.97%↓ Y/Y)
Other current
liabilities-Related Party
$157K
(28.69%↑ Y/Y)
Back
Back
Balance Sheet
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)
source: myfinsight.com